Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.

Cost-utility analysis of de-escalating biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.

<h4>Objective</h4>Recent guideline updates have suggested de-escalating DMARDs when patients with rheumatoid arthritis achieve remission or low disease activity. We aim to evaluate whether it is cost-effective to de-escalate the biological form of DMARDs (bDMARDs).<h4>Methods</h...

Full description

Saved in:
Bibliographic Details
Main Authors: Benjamin Birkner, Jürgen Rech, Tom Stargardt
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0226754&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items